Clinical Trial

A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Study acronym: XY0206-CQT
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg. After taking the corresponding investigational product, participants are required to complete test procedures including QTc interval measurement , blood sampling, and vital sign monitoring. The entire test process lasts for 3 days. On the third day, after participants complete laboratory tests and are assessed by physicians as meeting the discharge criteria, they can be discharged.
Trial Details
NCT Number NCT07162116
Lead Sponsor Shijiazhuang Yiling Pharmaceutical Co. Ltd
Conditions Acute Myeloid Leukemia With FLT3/ITD Mutation
Enrollment 45 participants
Start Date 2025-07-06
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-09